Who are Vesicare's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Northera, Evoxac, Detrol, Atrovent, Provocholine, Flaxedil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/solifenacin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Vesicare — Competitive Intelligence Brief

Vesicare (SOLIFENACIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinergic Muscarinic Antagonist. Area: Urology.

marketed Cholinergic Muscarinic Antagonist Muscarinic acetylcholine receptor M1 Urology Small molecule Live · refreshed every 30 min

Target snapshot

Vesicare (SOLIFENACIN) — Astellas Pharma. Vesicare works by blocking the action of a chemical called acetylcholine at the muscarinic receptors in the bladder muscle, reducing muscle contractions and urgency.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vesicare TARGET	SOLIFENACIN	Astellas Pharma	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	2004-01-01
Northera	DROXIDOPA	Lundbeck Na Ltd	marketed	Catecholamine	Muscarinic acetylcholine receptor M1	2014-01-01
Evoxac	CEVIMELINE	Cosette	marketed	Cholinergic Receptor Agonist	Muscarinic acetylcholine receptor M1	2000-01-01
Detrol	TOLTERODINE	Upjohn	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	1998-01-01
Atrovent	IPRATROPIUM		marketed	Anticholinergic	Muscarinic acetylcholine receptor M1	1986-01-01
Provocholine	METHACHOLINE	Methapharm	marketed	Cholinergic Receptor Agonist	Muscarinic acetylcholine receptor M1	1986-01-01
Flaxedil	GALLAMINE	Davis And Geck	marketed	gallamine	Acetylcholine receptor subunit alpha, Acetylcholinesterase, Muscarinic acetylcholine receptor M1	1982-01-01

Recent regulatory actions (last 90 days)

2026-02-23 — Atrovent · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholinergic Muscarinic Antagonist class)

· 2 drugs in this class
AbbVie · 2 drugs in this class
Astellas Pharma · 1 drug in this class
Hisamitsu Pharmaceutical Co., Inc. · 1 drug in this class
Upjohn · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vesicare — Competitive Intelligence Brief. https://druglandscape.com/ci/solifenacin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab